EXPERTISE

Jean-Hyacinthe is a partner within Gide’s Intellectual Property, Telecommunications, Media & Technology (IP-TMT) practice group. He specialises in industrial property and advises a number of French and foreign operators looking to protect and build on their intangible assets. In contentious matters, he covers infringement and agreements having a strong IP and/or technology content. In non-contentious matters, he advises companies in drafting and negotiating IP-related contracts, in particular as part of corporate operations (IPOs, venture capital, joint ventures, acquisitions, etc.).

EDUCATION

Jean-Hyacinthe is a graduate of Sciences Po Paris (2001) and Paris II – Panthéon-Assas University (postgraduate degree in literary, artistic and industrial property law, 2003).

RECENT OPERATIONS

He recently advised various investors (Idinvest Partners, CDC International, Serena Capital, Kennet Partners, Samsung Venture and Siparex) on their investments in European technology companies (in particular Devialet, Molotov, Nuxeo, Financefox, Secret Escapes), and in other companies such as happn, Storefront, Dataiku, Coorpacademy, DJiT and Launchmetrics during their funding rounds or flips in the USA.

RANKINGS

Chambers Europe 2017 – Intellectual Property (Band 1)

« Great reactivity, very knowledgeable lawyers who are also pragmatic and have an excellent understanding of the clients’ needs. »

Legal 500 2017 – Intellectual Property: Patents (Tier 1)

Gide Loyrette Nouel ‘knows how to best defend its clients’ interests’. The ‘high–level’ team is involved in domestic and multi-jurisdictional patent proceedings in electronics, mechanical products and pharmaceuticals.

Legal 500 2017 – Intellectual Property: Trade marks, designs and copyrights (Tier 1)

Gide Loyrette Nouel provides ‘an excellent overall level of service’ and represents many prestigious French and global brands. The firm recently achieved great results in several cases.

Décideurs 2017

An “unavoidable” team in Brands, designs and models, Patent disputes, and Healthcare – Patent disputes in Pharma, Biotechs and Lifesciences